Mononuclear blood cell magnesium content and serum magnesium concentration in critically ill hypomagnesemic patients after replacement therapy

Nutrition ◽  
1997 ◽  
Vol 13 (4) ◽  
pp. 303-308
Author(s):  
Gordon S. Sacks ◽  
Rex O. Brown ◽  
Roland N. Dickerson ◽  
Syamal Bhattacharya ◽  
Phuong-Dung Lee ◽  
...  
2017 ◽  
Vol 34 (11-12) ◽  
pp. 967-972 ◽  
Author(s):  
Drayton A. Hammond ◽  
Jelena Stojakovic ◽  
Niranjan Kathe ◽  
Julie Tran ◽  
Oktawia A. Clem ◽  
...  

Background: “Rules of thumb” for the replacement of electrolytes, including magnesium, in critical care settings are used, despite minimal empirical validation of their ability to achieve a target serum concentration. This study’s purpose was to evaluate the effectiveness and safety surrounding magnesium replacement in medically, critically ill patients with mild-to-moderate hypomagnesemia. Methods: This was a single-center, retrospective, observational evaluation of episodes of intravenous magnesium replacement ordered for patients with mild-to-moderate hypomagnesemia (1.0-1.9 mEq/L) admitted to a medical intensive care unit from May 2014 to April 2016. The primary effectiveness outcome, achievement of target serum magnesium concentration (≥2 mEq/L) compared to expected achievement using a “rule of thumb” estimation that 1 g intravenous magnesium sulfate raises the magnesium concentration 0.15 mEq/L, was tested using 1-sample z test. Logistic regression analysis was conducted to assess the effect of infusion rate on target achievement. Results: Of 152 days on which magnesium replacements were provided for 72 patients, a follow-up serum magnesium concentration was checked within 24 hours in 89 (58.6%) episodes. Of these 89 episodes, serum magnesium concentration reached target in only 49 (59.8%) episodes compared to an expected 89 (100%; P < .0001). There was no significant association between infusion rate and achievement of the target serum magnesium concentration (odds ratio: 0.962, 95% confidence interval: 0.411-2.256). Conclusions: Medically, critically ill patients who received nonprotocolized magnesium replacement achieved the target serum magnesium concentration less frequently than the “rule of thumb” estimation predicted.


2017 ◽  
Vol 37 (12) ◽  
pp. 1297-1303 ◽  
Author(s):  
D Narasimhulu ◽  
A Brown ◽  
N M Egbert ◽  
M Rojas ◽  
S Haberman ◽  
...  

2010 ◽  
Vol 55 (4) ◽  
pp. B45
Author(s):  
Nisha Bhatt ◽  
George Bayliss ◽  
M. Rachel Sim ◽  
Suzanne Martin ◽  
Jacqueline Wolf ◽  
...  

Blood ◽  
1962 ◽  
Vol 20 (6) ◽  
pp. 722-729 ◽  
Author(s):  
STANLEY GINSBURG ◽  
JAMES G. SMITH ◽  
FREEMAN M. GINSBURG ◽  
JACQUELINE Z. REARDON ◽  
JERRY K. AIKAWA

Abstract A modification of the magnesium ammonium phosphate precipitation method for the determination of serum magnesium was devised to determine the magnesium content of erythrocytes. The concentration of magnesium in the red cells of healthy hospital personnel was 4.67 ± 0.92 mEq./L. An increase in erythrocyte magnesium concentration was observed in patients with reticulocytosis. Experimental production of reticulocytosis by the administration of phenylhydrazine to rabbits confirmed these clinical observations. No significant in vitro uptake of Mg28 from the suspending medium occurred in mature human erythrocytes or in mature or immature erythrocytes from rabbits. The relative tissue uptake of Mg28 in the bone marrow was significantly increased in animals in whom anemia and marked reticulocytosis were produced by phenylhydrazine. Relative activity was decreased in the hearts, spleens, and kidneys of these animals. Since there is no evidence for significant exchange of magnesium in immature or mature erythrocytes in the peripheral circulation, it is concluded that the magnesium content of erythrocytes is increased in the bone marrow prior to their release into the peripheral circulation.


2019 ◽  
Vol 21 (12) ◽  
pp. 1172-1180 ◽  
Author(s):  
Fernanda Chicharo Chacar ◽  
Marcia Mery Kogika ◽  
Andréa C Ferreira ◽  
Khadine K Kanayama ◽  
Archivaldo Reche

ObjectivesMagnesium has been ‘the forgotten ion’ for many years. Over the past decade, however, the role of magnesium in essential physiological functions and several illness conditions have been elucidated. Nevertheless, the investigation of magnesium in cats with chronic kidney disease (CKD) and nephrolithiasis is yet to be determined. The purpose of this study was to investigate whether CKD cats with nephrolithiasis have changes in total serum magnesium concentrations, and whether magnesium disorders may be associated with other electrolyte disturbances, as well as with prognosis. We also aimed to evaluate whether total serum magnesium concentration differs between CKD cats with and without nephrolithiasis.MethodsTotal serum magnesium concentrations were assessed in 42 cats with CKD with stage 1–4 nephrolithiasis. The correlation between magnesium and other electrolytes, as well as Kaplan–Meier survival analysis, were performed. We also selected 14 control cats with CKD without nephrolithiasis age-matched with 14 cats with CKD with nephrolithiasis.ResultsHypermagnesemia was observed in 16/42 (38.1%) and hypomagnesemia in 6/42 (14.3%) cats. Serum magnesium abnormalities were observed in cats of all stages, and marked hypermagnesemia was noted in cats with stage 4 CKD with nephrolithiasis ( P <0.001). There was a negative correlation between total serum magnesium and ionized calcium ( r = −0.64; P <0.01), and a positive correlation between total serum magnesium and serum phosphorus ( r = 0.58, P = 0.01). Cats with CKD with nephrolithiasis and hypomagnesemia or hypermagnesemia had higher mortality than those with normal total serum magnesium concentration ( P <0.01), regardless of CKD stage. There was no difference in total serum magnesium concentration between CKD cats with and without nephrolithiasis.Conclusions and relevanceCats with CKD with nephrolithiasis have magnesium abnormalities. Hypomagnesemia and hypermagnesemia were associated with an increase in mortality, and thus total serum magnesium abnormalities may be used as prognostic factors in these cases.


2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Jun Lu ◽  
Yuying Gu ◽  
Meixiang Guo ◽  
Peihong Chen ◽  
Hongtao Wang ◽  
...  

Aim. To investigate the association between serum magnesium levels and microvascular complications among patients with diabetes.Methods. Patients with diabetes were recruited between April 2012 and January 2015. All patients received an assay of serum magnesium concentration, were screened for 24 h albumin excretion rate, and underwent nonmydriatic fundus photography. Albuminuria and retinopathy were defined accordingly. A total of 3,100 patients with normal serum magnesium levels were included in this study.Results. Patients with albuminuria and/or retinopathy had lower levels of serum magnesium than patients without these complications (P<0.001). The prevalence of isolated albuminuria, isolated retinopathy, and combined albuminuria and retinopathy decreased as the concentration of serum magnesium increased. Multiple logistic regression analysis indicated that the odds ratio for isolated albuminuria, isolated retinopathy, and concomitant albuminuria and retinopathy decreased by approximately 20% for every 0.1 mmol/L increase in serum magnesium concentration.Conclusion. Serum magnesium levels were negatively associated with the risk of diabetic microvascular complications among patients with serum magnesium levels within the normal range.


2008 ◽  
Vol 18 (4) ◽  
pp. 151-159 ◽  
Author(s):  
Yoriko Akizawa ◽  
Sadayuki Koizumi ◽  
Yoshinori Itokawa ◽  
Toshiyuki Ojima ◽  
Yosikazu Nakamura ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document